Hector Brunet Rodriguez, MD
Infectious Disease · Shreveport, LANPI 1104075290
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $417,036 of the $591,544 with a category attached, or 70.5%. 22 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 48.0% of the total. Reporting peaked in 2023 at $137,393 and has fallen 50.1% since, to $68,574 in 2025. Among infectious disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,327 payments — averaging $445.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$284K
- AbbVie$92K
- Gilead$67K
- Shionogi Inc$59K
- Melinta Therapeutics, LLC$44K
- Ferring Pharmaceuticals Inc.$23K
- plus $23K from 16 others
What the payments were for
- Consulting fees$12,4882%
- Speaking & faculty fees$417,03670%
- Travel & lodging$127,89922%
- Food & beverage$32,2065%
- Education$1,9150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 468 | $283,716 |
| AbbVie(2 entities) | 276 | $91,847 |
| Gilead | 102 | $67,037 |
| Shionogi Inc | 99 | $58,587 |
| Melinta Therapeutics, LLC | 89 | $44,480 |
| Ferring Pharmaceuticals Inc. | 55 | $22,841 |
| Insmed, Inc. | 47 | $17,865 |
| Astellas Pharma US Inc | 57 | $1,554 |
| Merck | 65 | $1,359 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $557 |
| Johnson & Johnson(2 entities) | 15 | $422 |
| Viiv Healthcare Company | 13 | $259 |
| Pfizer | 8 | $256 |
| Theratechnologies Inc. | 10 | $233 |
| La Jolla Pharmaceutical Company | 3 | $172 |
| Aimmune Therapeutics, Inc. | 4 | $140 |
| Mayne Pharma Commercial LLC | 4 | $80 |
| Electromed, Inc. | 2 | $48 |
| Janssen Products, LP | 1 | $31 |
| Biomerieux Inc | 1 | $24 |
| KCI USA, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$591,544 in reported general payments places this provider in the 95th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 21 | $47,292 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $45,782 |
| Daptomycin | 53 | $45,539 |
| ErtapenemErtapenem Sodium | 18 | $6,890 |
| Itraconazole | 16 | $4,558 |
| Fosfomycin Tromethamine | 15 | $3,967 |
| Cefepime Hcl | 17 | $3,672 |
| Lamivudine-ZidovudineLamivudine/Zidovudine | 12 | $1,249 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $712 |
| Cefazolin Sodium | 11 | $613 |
| Doxycycline Hyclate | 23 | $558 |
| Cephalexin | 28 | $547 |
| Levofloxacin | 13 | $341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTivicay | $259 | $47,29221 claims |
| GileadBiktarvy | $67,037 | $45,78212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 infectious disease providers in Louisiana.
Other infectious disease in Shreveport
- Guillermo Padilla-PinedaShreveport$106K
- Jihad El-HayekShreveport$11K
- Halim Abou FaycalShreveport$9K
- Paulette Pinargote CornejoShreveport$6K
- Mohammad AlamShreveport$5K
- Alexandre MalekShreveport$5K
- John ToddShreveport$4K
- Gerardo NegronShreveport$2K
- Aline ArifShreveport$2K
- Raymond CoghlanShreveport$601
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.